Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
62 Cards in this Set
- Front
- Back
5 Sites for drug metabolism
|
1) Liver
2) Intestines 3) Stomach 4) Kidney 5) Intestinal bacteria |
|
Main site of drug metabolism
|
Liver
|
|
Main thing metabolized in the stomach
|
Alcohol
|
|
Exogenous vs endogenous
|
Exogenous are things we put in our body
Endogenous are things created in our body that need metabolizing |
|
5 Goals of metabolism
|
1) Change a drug from lipophilic to hydrophilic to be excreted
2) Inactivate a substance 3) Make a substance more active 4) Activate a prodrug 5) Increase toxicity |
|
First order kinetics
|
Conc of drug is lower than the metabolizing capacity of the body
|
|
What curve looks like in a first order kinetic graph
|
Conc decreases steadily as time increases
|
|
Zero order kinetics
|
Conc of drug is higher than the body's metabolizing capacity
|
|
What graph looks like in zero order kinetics
|
Linear graph decreasing as time goes on
|
|
First pass metabolism
|
Amount of drugs that are metabolized before entering the circulation
|
|
First pass metab in the stomach
|
Alcohol uses alcohol dehydrogenase to create acetaldehyde
|
|
First pass metab in the intestines
|
A drug uses a CYP enzyme to make a metabolite
|
|
First pass metab with intestinal bacteria
|
A drug uses bacterial enzymes to make a metabolite
|
|
First pass metab in the liver
|
A drug uses a CYP enzyme to make a metabolite
|
|
Extraction ratio
|
Depends on how much metabolism occurs during first pass
|
|
A high extraction ratio implies a ___ oral bioavailability and therefore requires a ___ dose than IV
|
Low, higher
|
|
High or low extraction ratio drugs are susceptible to drug-drug interactions
|
High
|
|
What phase is it when lipophilic drugs are converted to more polar molecules
|
Phase 1
|
|
What phase is it when drugs undergo oxidation, reduction, and hydrolysis
|
Phase 1
|
|
What phase of metabolism is mediated by cytochrome p450, esterase's, and dehydrogenases
|
Phase 1
|
|
What phase is it when conjugation reactions occur?
|
Phase 2
|
|
What is a conjugation reaction
|
More water soluble molecules are added to the drug
|
|
4 water soluble molecules added to the drug during conjugation
|
Glucuronic acid, sulfate, acetate, or amino acids
|
|
Metabolites generated in phase 2 metabolism are more/less active?
|
Less
|
|
What is the exception to the phase II activity rule (Drugs become less active normally)
|
Morphine is metabolized to morphine 6 glucuronide, which is more potent than morphine
|
|
Sites of phase 1 and phase 2 metabolism
|
1) Smooth ER
2) Cytoplasm |
|
What is the exception to the locations of the phases of metabolism
|
Glucuronidation occurs in the SER, not cytoplasm
|
|
What is the largest family of drug metabolizing enzymes
|
CYP
|
|
What is the majority of drug metabolism performed by
|
CYP
|
|
Mechanism of action of CYP
|
Oxidation by adding 1 O2 atom to the molecule, creating water as a by-product
|
|
Main factor affecting CYP activity
|
Nutrition
|
|
How to name CYP 3A4
|
3 - Family, A - sub-family, and 4 - isozyme
|
|
5 types of Phase II metabolizers
|
1) UGT's
2) SULTs 3) GST's 4) NAT's 5) TPMT |
|
UGT mechanism of action
|
Located in SER
Catalyze glucuronidation Increase polarity |
|
SULTs mechanism of action
|
Catalyze transfer of sulfate to hydroxyl group on a drug
Increase polarity |
|
GST's mechanism of action
|
Catalyze transfer of glutathione to drug
Lowers toxicity |
|
NAT's mechanism of action
|
Transfers acetyl group from acetylcoA to drug
Increases water solubility |
|
TPMT mechanism of action
|
Transfer methyl to drug
|
|
What 2 drug metabolizers are most susceptible to genetic polymorphisms
|
NAT and TPMT
|
|
4 Factors affecting drug metabolism
|
1) Age
2) Drug interactions 3) Disease state 4) Genetic polymorphisms |
|
When does drug metabolism become fairly strong
|
2-17
|
|
What is enzyme induction
|
A cell synthesizes an enzyme in response to presence of a drug
|
|
3 possible consequences of drug enzyme induction
|
Lower plasma conc.
Decreased drug activity (Inactive metabolite) Increased drug activity (Active metabolite) |
|
3 Consequences of enzyme inhibition
|
1) Higher plasma conc.
2) Higher therapeutic effect 3) Higher chance of toxicity |
|
Disease _____ CYP activity
|
Decreases
|
|
CYP 2C9 metabolizes
|
Warfarin
|
|
Warfarin is metabolized by what enzyme
|
CYP 2C9
|
|
A SNP in CYP 2C9 would cause
|
Lower enzyme activity, increased risk of bleeding
|
|
CYP 2D6 metabolizes
|
Codeine - Morphine
|
|
Codeine is metabolized by what enzyme
|
CYP 2D6
|
|
4 Possible consequences of a CYP 2D6 SNP
|
Ultra-rapid metabolizer
Extensive metabolizer Intermediate metabolizer Poor metabolizer |
|
Consequences of a UM SNP of CYP 2D6
|
Ultra rapid metabolizer - Decreased plasma conc and therapeutic response
|
|
Consequences of a EM SNP of CYP 2D6
|
Extensive metabolizer - Normal CYP activity
|
|
Consequences of a IM SNP of CYP 2D6
|
Intermediate metabolizer - Decreased CYP activity - Higher therapeutic response, higher plasma conc
|
|
Consequences of a PM SNP of CYP 2D6
|
Poor metabolizer - Almost no activity - Dangerous therapeutic response, very high plasma conc
|
|
UGT 1A1's mechanism of action
|
Glucuronidates anti-cancer compound SN-38
|
|
Anti-cancer compound SN 38 is metabolized by
|
UGT 1A1
|
|
SNP of UGT 1A1 causes
|
Less enzyme activity
Diarrhea dose limiting bone marrow suppression |
|
NAT2's mechanism of action
|
Acetylates isoniazid (TB treatment)
|
|
Isoniazid is used for what, and is metabolized by what
|
TB , NAT2
|
|
A rapid SNP of NAT2 will cause
|
High response to isoniazid - Ineffective treatment of TB
|
|
A slow SNP of NAT2 will cause
|
Isoniazid toxicity - High cancer risk
|